NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alector, Inc. (ALEC) Stock Analysis

Alector, Inc. (ALEC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALEC

$1.87

−$0.10 (−5.08%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALEC with… →

ALEC Key Statistics

As of Oct 21, 2026
Trading
Open
$1.97
Previous Close
$1.97
Day's Range
1.85–2.00
52-Week Range
1.09–2.76
Volume
1.11M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$208.80M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
15.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.09
Financials (FY)
Revenue (FY)
$21.05M−79.07%
Net Income (FY)
−$142.93M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
111.66M
1-Year Return
−41.74%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALEC closed at $1.87, −41.74% over 1 year.

Alector, Inc. (ALEC) has a market capitalization of $208.80M.

In fiscal 2025, ALEC reported revenue of $21.05M.

ALEC Stock Return by Calendar Year

Alector, Inc. (ALEC) return since Feb 2019: what $10,000 became

1 year
$10,000 $5,826
−41.74%
5 years
$10,000 $788
−92.12%
Since Feb 2019
$10,000 $1,034
−89.66%

If you had invested $10,000 in Alector, Inc. (ALEC) at the close on February 7, 2019, the earliest close on record here, it would have been worth $1,034 at the close on October 21, 2026: −89.66% in total, −25.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+19.87%
2025−17.46%
2024−76.32%
2023−13.54%
2022−55.30%
2021+36.48%
2020−12.19%
2019 (partial year)−4.70%

As of October 21, 2026.

ALEC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$21.05M−$142.93M−679.2%
2024$100.56M−$119.05M−118.4%
2023$97.06M−$130.39M−134.3%
2022$133.62M−$133.31M−99.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$21.05M—−$156.01M−$142.93M−679.2%
2024$100.56M—−$145.00M−$119.05M−118.4%
2023$97.06M—−$151.74M−$130.39M−134.3%
2022$133.62M—−$137.83M−$133.31M−99.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALEC Valuation vs Biotechnology Median

Median of 608 stocks
MetricALECBiotechnology medianvs median
P/S ratio15.0613.3013% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alector, Inc. (ALEC) is capitalised at $208.80M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 103.

The most recent close on file for ALEC is $1.87, dated October 21, 2026. That is −$0.10 (−5.08%) against the previous close. The 52-week range on file runs from $1.09 to $2.76. The latest close sits 71.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $21.05M. Against the prior fiscal year total of $100.56M, that is a change of −79.07%. The same year closed with a net loss of $142.93M. Earnings per share on a trailing basis come to −1.09.

Across the 4 fiscal years on file, revenue moves from $133.62M in 2022 to $21.05M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 15.06 times revenue. On price-to-sales that is 13.26% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −41.74%. Measured over 5 years, that is −39.84% a year compounded. Beta against the wider market is reported at 0.62. Annualized volatility over the trailing 7 years is 86.14%.

Growth & Income

The record shows no dividend for ALEC.

So far in 2026 the total return is +19.87%. The strongest complete calendar year on file is 2021 at +36.48%; the weakest is 2024 at −76.32%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Alector, Inc. (ALEC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alector, Inc. ALEC $208.80M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alector, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alector, Inc.

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Visit website →